Clinical Evaluation of Silk'n Glide for Face

Home Skinovations Ltd.17 enrolled

Overview

This is a clinical study to determine the efficacy and safety of the Glide, hair removal photo-depilation device, for removing facial hairs. During the first stage, the subjects will perform up to 6 face treatments, two weeks apart. The treatment's safety and efficiency will be evaluated at 4 weeks of after last treatment and at 12 weeks after last treatment.

Study efficacy assessment: Comparison of hair counts before treatments to 4 and 12 weeks follow up visits. Study safety assessment: 1. Reported errors and near errors using the device 2. Device malfunctions which relate to device safety 3. Device related adverse events 4. Non device related adverse events (secondary endpoint)

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hirsutism

Interventions

GlideDEVICE

6 facial hair reduction treatments with the Glide device, two weeks apart.

Eligibility

Sex: ALLMin age: 21 YearsMax age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Presence of unwanted hairs on the face 2. Skin Type I to IV (Fitzpatrick) 3. Adults older than 21 years of age but not more than 60 years of age. 4. Must be either post-menopausal or surgically steri-lized, or using a medically acceptable form of birth control (i.e., oral contraceptives, IUD, contraceptive implant, barrier methods with spermicide or absti-nence). 5. Informed consent agreement by the subject. 6. Willingness to follow the treatment schedule and post treatment care. Exclusion Criteria: 1. Malignant or pre-malignant pigmented lesions in the area to be treated. 2. Scarring or infection of the area to be treated. 3. Known photosensitivity. 4. Pregnancy or lactating 5. Subjects with Diabetes (Type I or II). 6. Presence of a suntan in the area to be treated. 7. Use of medication known to induce photosensitivity. 8. Subject is on anticoagulative medication or throm-boembolic condition. 9. Subjects with a pacemaker or internal defibrillator. 10. Use of NSAIDS two weeks prior to, and two weeks following the treatment. 11. Subjects that use waxing or other methods of photo-epilation 3 months prior to treatment. 12. Subjects that have been exposed to strong sunlight or an artificial tanning machine during the past 4 weeks 13. Subjects wearing a tattoo or permanent makeup on the area to be treated 14. Subjects with dark brown or black spots, such as large freckles, birth marks, moles or warts on the area to be treated 15. Subjects with Eczema, psoriasis, lesions, open wounds or active infections, such as cold sores in the area to be treated 16. Subjects with history of keloidal scar formation 17. Subjects with history of herpes outbreaks in the area of treatment, unless you have consulted your physician and received preventative treatment before using GlideTM 18. Subjects with epilepsy 19. Subjects using incontinence device, insulin pump, other active devices \[NB: Protocol excludes pace-makers and internal defibrillators.\] 20. Subjects with a history of skin cancer or areas of po-tential skin malignancies 21. Subjects who have received radiation therapy or chemotherapy treatments within the past 3 months

Outcomes

Primary Outcomes

1. Comparison of Hair Counts Before Treatments to 4 and 12 Weeks Follow up Visits.

Hair count is going to be preformed and base line and compare with the count at 4 weeks and 12 weeks. % of hair reducation is going to be calculated.

Time frame: 4 weeks and 12 weeks post treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.